Trial Title: Developmental Outcomes of Long-term Feed Supplementation in Neonates - The DOLFIN randomised controlled trial

Internal Reference Number / Short title: NuTH REF: 9707

Ethics Ref: 22/SW/0009

IRAS Project ID: 303421

Date and Version No: V3.0 09/06/2022

Chief Investigator (with overall Chief Investigator responsibility):	Professor Jeremy Parr Professor of Paediatric Neurodisability University of Newcastle upon Tyne Email: jeremy.parr@newcastle.ac.uk
Co-Chief Investigator (as per NIHR award):	Dr Morag Andrew Consultant Paediatrician The Newcastle upon Tyne Hospitals NHS Foundation Trust Email: morag.andrew@newcastle.ac.uk
Sponsor:	The Newcastle upon Tyne Hospitals NHS Foundation Trust
Funder:	NIHR HTA programme – NIHR130925

Chief Investigator Signature:

Co-Chief Investigator Signature:

Statistician Signature:

There are no conflicts of interest to declare.

Confidentiality Statement

This document contains confidential information that must not be disclosed to anyone other than the Sponsor, the Investigator Team, HRA, host organisation, and members of the Research Ethics Committee and Regulatory Authorities unless authorised to do so.

TABLE OF CONTENTS

1. KEY TRIAL CONTACTS

Chief Investigator (with overall Chief Investigator responsibility)	Professor Jeremy Parr Professor of Paediatric Neurodisability University of Newcastle upon Tyne Population Health Science Institute Honorary Consultant Neurodisability Paediatrician The Newcastle upon Tyne Hospitals NHS Foundation Trust Email: jeremy.parr@ncl.ac.uk.ac.uk Telephone: 01912825965
Co-Chief Investigator as per NIHR award:	Dr Morag Andrew Consultant Paediatrician The Newcastle upon Tyne Hospitals NHS Foundation Trust Email: morag.andrew@ncl.ac.uk Telephone: 0191 2829312
Sponsor	The Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle Joint Research Office Level 1, Regent Point Regent Farm Road Gosforth Newcastle upon Tyne NE3 3HD Email: tnu-tr.sponsormanagement@nhs.net Telephone: 01912824454
Funder	NIHR HTA programme - NIHR 130925
Clinical Trials Unit	NPEU Clinical Trials Unit National Perinatal Epidemiology Unit Nuffield Department of Population Health University of Oxford Old Road Campus Oxford OX3 7LF

	Telephone: 01865 617919 Email: dolfin@npeu.ox.ac.uk
Statistician	Pollyanna Hardy NPEU Clinical Trials Unit National Perinatal Epidemiology Unit Nuffield Department of Population Health University of Oxford Old Road Campus Oxford OX3 7LF Telephone: 01865 289743 Email: pollyanna.hardy@npeu.ox.ac.uk

2. SYNOPSIS

Trial Title	Developmental Outcome of Long-term Feed Supplementation in Neonates - The DOLFIN randomised controlled trial
Internal ref. no. (or short title)	NuTH REF: 9707
Trial registration	ISRCTN: 62323236
Sponsor	The Newcastle upon Tyne Hospitals NHS Foundation Trust
Funder	NIHR HTA programme – NIHR 130925
Clinical Phase	Phase III
Trial Design	Multicentre, blinded, stratified, randomised placebo-controlled trial with an internal pilot and alongside economic evaluation. Strata are defined as (1) infants born < 28 weeks of gestation and (2) infants born at ≥ 35 weeks of gestation receiving therapeutic hypothermia for Hypoxic Ischaemic Encephalopathy (HIE)
Trial Participants	Stratum 1. Infants born less than 28 weeks of gestation (preterm stratum) Stratum 2. Infants born at 35 weeks of gestation or more receiving therapeutic hypothermia for HIE (HIE stratum) Infants will be recruited from approximately 30 UK NHS tertiary Neonatal Units.
Sample Size	1,010 infants; 538 infants for the preterm stratum, and 472 infants for the HIE stratum. Both strata are powered to detect a 6 point difference between the two arms on the PARCA-R non-verbal cognitive scale standardised score, with 90% power and a 2-sided 5% significance, assuming a population mean score of 88 and standard deviation of 19. An inflation factor of 14% is applied to the preterm stratum to allow for clustering within multiple births. Prevalence of multiple births in the HIE stratum is expected to be negligible.
Planned Trial Period	Trial duration: 69 months Duration of participant involvement: • Intervention phase: to 12 months post Estimated Date of Delivery (EDD). • Follow up phase: to 24 months post EDD.
Planned Recruitment period	Approximately 27 months
Aims: Primary:	To evaluate whether nutritional supplementation with a nutrient blend containing long-chain polyunsaturated fatty acids (LCPUFAs), choline, uridine-5'-Monophosphate (UMP), and cytidine-5'- monophosphate (CMP) plus usual care from birth to 12 months post EDD improves cognitive development at 24 months post EDD, compared to infants receiving a matched placebo supplement plus usual care (comparator), for (1) infants

Secondary:	born <28 weeks of gestation and (2) infants born at ≥ 35 weeks of gestation receiving therapeutic hypothermia for HIE. To evaluate whether nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP and CMP plus usual care from birth to 12 months post EDD alters the following outcomes compared to infants receiving a matched placebo supplement plus usual care (comparator), for (1) infants born <28 weeks of gestation and (2) infants born at ≥ 35 weeks of gestation receiving therapeutic hypothermia for HIE: • neurodevelopmental outcomes: language; motor; emotional, conduct, hyperactivity/inattention, peer relationship problems and prosocial behaviour at 24 months post EDD • infant growth, clinical outcomes, safety, infant tolerability, parental acceptability, maternal quality of life to 24 months post EDD • Health Economics outcomes
Objectives:	For each stratum separately:- <u>Primary</u> • To compare cognitive development of infants randomised to receive nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP compared to those randomised to receive matched placebo, at 24 months post EDD. <u>Secondary</u> • To compare the effects of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP with matched placebo on secondary neurodevelopmental outcomes, at 24 months post EDD. • To investigate the effect of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP on infant growth outcomes to 24 months post EDD. • Investigate the effect of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP on clinical outcomes up to discharge. To investigate the safety, infant tolerability, adherence to and parental acceptability of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP to 12 months post EDD. Safety monitoring will continue for two weeks after the end of the intervention period. • To investigate the impact of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP on maternal health-related quality of life to 24 months post EDD.

	• To investigate the cost-effectiveness of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP in relation to health and social care resource use, and wider societal implications including family expenses, paid employment and informal care.
Intervention(s)	Micronutrient breast milk/formula milk/food supplement containing a nutrient blend containing LCPUFAs, choline, UMP, and CMP. Powder supplement added daily to usual milk feed (breast or formula) on the neonatal unit when infants reach full milk feeds (120–150ml/kg/day). HIE stratum babies can start supplementation post-discharge if required. Supplementation continued on discharge and given at home by parents until 12 months post EDD.
Comparator	Matched placebo control supplement: identically packaged and delivered powder supplement indistinguishable from the active treatment. Powder supplement added daily to usual milk feed (breast or formula) on the neonatal unit when infants reach full milk feeds (120-150ml/kg/day). HIE stratum babies can start supplementation post-discharge if required. Supplementation continued on discharge and given at home by parents until 12 months post EDD.

3. FLOW CHART



4. ABBREVIATIONS

AE	Adverse Event
AR	Adverse Reaction
ASQ-3	Ages and Stages Questionnaire, Third Edition
CEAC	Cost-effectiveness acceptability curves
CI	Confidence Interval
CI	Chief Investigator
CMP	Cytidine-5'-Monophosphate
CRF	Case Report Form
CRN	Clinical Research Networks
CTA	Clinical Trials Authorisation
CTRG	Clinical Trials and Research Governance
DBM	Donor Breast Milk
DHA	Docosahexaenoic Acid
DMC	Data Monitoring Committee
DSUR	Development Safety Update Report
EBM	Expressed Breast Milk
EDD	Estimated Date of Delivery
EP	Extreme preterm
EPA	Eicosapentaenoic Acid
ESPGHAN	European Society for Paediatric Gastroenterology Hepatology and Nutrition
GCP	Good Clinical Practice
GP	General Practitioner
HEAP	Health Economics Analysis Plan
HIE	Hypoxic Ischaemic Encephalopathy
HRA	Health Research Authority
IB	Investigator's Brochure
ICER	Incremental Cost-Effectiveness Ratio
ICF	Informed Consent Form
ICH	International Conference on Harmonisation
IMP	Investigational Medicinal Product
JLA PSP	James Lind Alliance Priority Setting Partnership

LCPUFA	Long Chain Polyunsaturated Fatty Acid
MHRA	Medicines and Healthcare products Regulatory Agency
NHS	National Health Service
NGT	Nasogastric Tube
NICE	National Institute for Health and Care Excellence
NNU	Neonatal Unit
NPEU CTU	National Perinatal Epidemiology Unit Clinical Trials Unit
RES	Research Ethics Service
PARCA-R	Parent Report of Children's Abilities-Revised
PI	Principal Investigator
PIL	Participant/Patient Information Leaflet
QALY	Quality-Adjusted Life Years
R&D	NHS Trust R&D Department
RCT	Randomised Control Trial
REC	Research Ethics Committee
RSI	Reference Safety Information
SAE	Serious Adverse Event
SAR	Serious Adverse Reaction
SDQ	Strengths and Difficulties Questionnaire
SDV	Source Data Verification
SEN	Special Educational Needs
SFS	Supplemental Feeding System
SOP	Standard Operating Procedure
SUSAR	Suspected Unexpected Serious Adverse Reaction
TMF	Trial Master File
UMP	uridine-5'-monophosphate
WASI	Wechsler Abbreviated Scale of Intelligence

5. BACKGROUND AND RATIONALE

Nutrients DHA, choline and UMP are particularly important for brain development and may improve neurodevelopmental outcomes[1,2]. The Dolphin neonatal external pilot RCT used a micronutrient active supplement (a nutrient blend containing LCPUFAs, choline, UMP, and CMP) given for 24 months in newborns at risk of neurological impairment[3]. A total of 59 neonates were randomised. Treatment was feasible and acceptable to families and professionals. No active nor placebo supplement-related serious adverse events or safety concerns were reported. The primary outcome was the Bayley Scales of Infant and Toddler Development III Cognitive Scale[4], following supplementation for 24 months. The treatment group had higher mean cognitive scale scores (mean difference: 9·0 (95% confidence interval (CI) (-0·2 to 18·2)), and language scale scores (mean difference: 8·6, 95% CI (-1·1 to 18·2)) compared to the placebo control group. There was little (between group) difference in mean motor scale scores (mean difference: -1.2 (95% CI (-11.9 to 9.5)). Parent reports of neurodevelopmental outcomes showed similar results[3]. The parallel Dolphin infant trial (infants age 1-18 months; n=40) reported similar findings[5]. Pre-school follow-up studies (at age 4–6 years) showed treatment group advantage (increase of 8.9 IQ points (95% CI: -4.4, 22.2) in cognitive development/IQ (assessed by the Kaufman Assessment Battery for Children II)[6] compared to controls (Andrew MJ et al, in preparation), as well as treatment group advantage in attention assessed by the Early Childhood Attention Battery subtests[7,8].

Our study includes infants at high risk of adverse neurodevelopmental outcomes. Children born extremely preterm have substantial cognitive deficits that are present in infancy and persist throughout childhood and adolescence, with deficits in IQ of a similar magnitude in adulthood as in childhood [9,10]. Up to 40% of extremely preterm children born at less than 26 weeks' gestation have moderate/severe learning difficulties and 2 in 3 have special education needs (SEN) by the end of primary education[11] resulting in reduced wealth, occupational status and economic potential in adulthood[12]. Fewer than half these infants have radiological evidence of brain injury. Infants born prematurely receive inadequate nutrient intake due to multiple challenges including high nutritional needs, prolonged parenteral nutrition, and delayed breastmilk supplementation; current nutritional protocols do not deliver sufficient DHA, choline and UMP.

Hypoxic Ischaemic Encephalopathy (HIE) is a clinical diagnosis of babies born at or near term. HIE often results in lifelong disability even in the absence of radiological abnormalities. Cognitive deficits, particularly in attention and executive functions, are identified in children following moderate-severe hypoxic ischaemic encephalopathy HIE [13,14,15]. The impact of these deficits on school attainment and social functioning are significant[16].

As these two infant populations are extremely heterogeneous, the trial is stratified for extremely preterm and HIE infant strata. Each stratum is separately powered and will be analysed separately.

The trial primary outcome measure is the Parent Report of Children's Abilities-Revised (PARCA-R) non-verbal cognitive scale score at 24 months of age (corrected for prematurity)[17]. The PARCA-R is a reliable and valid parent completed norm-referenced assessment from which age- and sex-standardised scores (Mean 100; SD 15) are derived for cognitive and language development[17]. It was used as an outcome measure in recent landmark perinatal trials (SIFT, INIS, INFANT), and is recommended for developmental surveillance of children born very preterm at age 2 years[18,19].

This trial aims to establish whether or not early life nutritional supplementation with LCPUFAs, choline, UMP, and CMP improves infants' cognitive development at 24 months post EDD, compared to controls, in two clearly defined strata:

1) Preterm stratum: Infants born less than 28 weeks of gestation

2) HIE stratum: Infants born at 35 weeks of gestation or more, receiving therapeutic hypothermia for HIE

6. OBJECTIVES AND OUTCOME MEASURES

For each stratum separately:-

	Objective	Outcome Measures and mode of data collection	Time point(s) (post EDD)
Primary*	To compare cognitive development of infants randomised to receive nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP compared to those randomised to receive matched placebo, at 24 months post EDD	Non-verbal cognitive scale standardised score of the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire	At 24 months
Secondary*	To compare the effects of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP with matched placebo on secondary neurodevelopmental outcomes, at 24 months post EDD	Language Development Scale standardised score of the PARCA-R questionnaire	At 24 months
		Parent reported emotional, conduct, peer problems, hyperactivity, prosocial and total score using the Strengths and Difficulties Questionnaire	
		Parent reported motor skills using the fine and gross motor scales score of the Ages and Stages Questionnaire (ASQ-3)	
	To investigate the effect of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP on infant growth	Weight standard deviation score	At 24 months
		Head circumference standard deviation score	
		Overweight or obese (BMI ≥ 85th percentile)	At 24 months

	outcomes to 24 months post EDD		
	Investigate the effect of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP on clinical outcomes up to discharge	Microbiologically-confirmed late-onset invasive infection	Up to discharge home from neonatal unit
		Necrotising enterocolitis requiring surgery	
		Retinopathy of prematurity treated medically/surgically (preterm stratum only)	
		Chronic lung disease (preterm stratum only)	
Secondary	To investigate the safety, infant tolerability, adherence to and parental acceptability of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP to 12 months post EDD	Safety and Adverse Events	Up to 12 months plus two weeks after the end of the intervention period
		Parent reported infant tolerability of supplement (IGSQ)	Discharge home from neonatal unit, 3, 6 and 12 months
		Parent reported adherence	Up to 12 months
		Parent reported acceptability of supplement	6 and 12 months
Secondary*	To investigate the impact of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP on maternal health-related quality of life up to 24 months post EDD	Maternal health-related quality of life using the EuroQol EQ-5D-5L questionnaire	Baseline, 6, 12, 18 and 24 months
		Maternal quality adjusted life years (QALYs)	Up to 24 months
Secondary*	To investigate the cost-effectiveness of nutritional supplementation with a nutrient blend containing LCPUFAs, choline, UMP, and CMP in relation to health and social care resource use, and wider	Health and social care resource use and costs and out-of-pocket costs incurred by families Productivity costs and informal care	Up to 24 months

	societal implications including family expenses, paid employment and informal care		
		Cost per life year without moderate/severe neurodevelopmental impairment (within-trial cost-effectiveness analysis)	At 24 months
		Cost per QALY gained (long-term cost effectiveness analysis)	Modelled to 18 years post EDD

*Listed outcomes will be compared between trial arms using formal statistical methods. All other outcomes will be described using summary statistics only.

TRIAL DESIGN

Trial design: Multicentre, blinded, stratified, randomised placebo-controlled trial (with internal pilot and integrated economic evaluation). Strata are defined as (1) infants born < 28 weeks of gestation (preterm stratum) and (2) infants born at ≥ 35 weeks of gestation receiving therapeutic hypothermia for HIE (HIE stratum).

This research will take place within UK NHS neonatal units and in participant homes. A 9-month internal pilot phase incorporates “stop-go” criteria to evaluate feasibility of recruitment and other trial processes (see section 7.1).

Trial data collection will be from trial entry until 24 months post EDD, including screening, consent, supplementation and follow-up. Outcome information will be collected by case report forms (CRFs), with clinical data collection from medical records at hospital sites. Participant weight and adherence to daily supplementation during the intervention period will be reported via a parent report and/or clinical services. Parental questionnaires will be completed at randomisation and then sent to the parent/carer after discharge and when the child is 3, 6, 12, 18 and 24 months post EDD. Consent will be obtained to invite parents to participate in future pre-school and school age follow-up studies and to obtain routinely collected education and health data.

6.1. Internal pilot

The internal pilot will assess site and participant recruitment as pre-specified progression criteria, separately for the two strata (preterm and HIE). Other measures will include: parental uptake (expected to be 50%); retention of participants (expected around 90%); acceptability of supplementation and

adherence by parents; safety; and completeness of data collection. Pre-defined stop-go criteria will be considered by the TSC to assess trial viability.

The length of the internal pilot will be 9 months (one-third of the total recruitment period of 27 months) and will aim to recruit one fifth of the target sample size of 1010 (202 infants). Assuming a monthly recruitment of 1.5 infants (0.8 preterm and 0.7 HIE) per centre by month 3, with centres taking 3 months to reach stable recruitment, 30 centres will have to be actively recruiting by month 9. The internal pilot will assess the following assumptions:

% Threshold	Red	Amber	Green
Sites open	<22	≥22	≥30
Preterm patient strata			
Recruitment per site per month	<0.6	≥0.6	≥0.8
Total participants recruited	<81	≥81	108
HIE patient strata			
Recruitment per site per month	<0.53	≥0.53	≥0.7
Total participants recruited	<70	≥70	94

Green: continue into the main trial
Amber: open new centres as appropriate, assess and address reasons for lower than anticipated recruitment, review in 6 months
Red: urgent detailed review of options with the TSC and funder

7. PARTICIPANT IDENTIFICATION

7.1. Trial participants

The trial population consists of two clearly defined strata:

(1) Preterm stratum - Preterm infants born less than 28 weeks of gestation

and

(2) HIE stratum - Infants born at 35 weeks of gestation or more who receive therapeutic hypothermia for hypoxic ischaemic encephalopathy (irrespective of neuroimaging findings).

7.2. Inclusion criteria

- Preterm stratum: Infants born less than 28 weeks of gestation, up to discharge home from NNU or step-down site, and no more than 3 months post EDD
- HIE stratum: Infants born at 35 weeks of gestation or more, who have received therapeutic hypothermia for HIE, up to 40 weeks of gestation plus 28 days
- Individual with parental responsibility able to give consent. In the event that the mother is unable to give consent, or does not have parental responsibility consent can be given by another

person who has parental responsibility. Maternal consent for the purposes of maternal data collection will be sought as soon as practical

- Parents able to comply with the protocol
- Infants likely to tolerate full enteral feeds
- Infant has realistic prospect of survival beyond discharge

7.3. Exclusion criteria

The infant is not eligible if ANY of the following apply:

- Infants with middle cerebral artery infarcts
- Infants with major congenital brain malformation, or genetic condition with abnormal brain development
- Infants with galactosaemia
- Infants receiving jejunal feeds

8. TRIAL PROCEDURES

8.1. Schedule of trial procedures

PROCEDURES	BEFORE TRIAL ENTRY	AFTER TRIAL ENTRY	AFTER TRIAL ENTRY							
	Screening	Baseline	Randomisation	Intervention and Data collection						
				Post-randomisation	Around hospital discharge	3 months post EDD	6 months post EDD	12 months post EDD	18 months post EDD	24 months post EDD
Eligibility assessment	X									
Informed consent		X								
Randomisation			X							
Supplement				X	X	X	X	X		
Parent completed baseline/outcome questionnaires				X	X	X	X	X	X	X
Parent completed tolerance questionnaire					X	X	X	X		
Acceptability questionnaire							X	X		
NHS clinical data collection		X	X		X					X
Adverse events assessments *(SAEs, SUSARs etc) throughout intervention period			X	X	X	X	X	X		

*safety monitoring occurs throughout the intervention period and will continue for two weeks after the end of the intervention period.

8.2. Completion of outcome measures

All infants will be followed up during the trial to 24 months post EDD. An electronic communication (e.g. via the app, email, WhatsApp, text message) will be used to prompt parents to complete and return questionnaires at randomisation, around discharge from NNU, 3 , 6, 12, 18 and 24 months post EDD. There will be an option to request hard copies of the questionnaires (contingent on COVID-19 risk assessment). A FREEPOST envelope will be supplied to families who opt to complete paper copies of the

questionnaires. Participants who do not complete the outcome measures will be contacted with a further request for completion. Thereafter, failure to complete the outcome questionnaires will trigger a phone call from a member of the local clinical team or from the research team to check if there are any barriers to completion and offer support in completing the questionnaires. Support may include, for example, an offer to complete the questionnaire over the phone at a time convenient to the family. If absolutely necessary, a home visit from the local research nurse may be offered if this is necessary to ensure the completion of outcome measures. Primary outcome (PARCA-R) and secondary outcome neurodevelopmental data will be shared with the local neonatologist or paediatrician, or GP for participants no longer under hospital follow-up; information about norms will be provided to aid local clinician interpretation. Participating families will be sent a £25 gift voucher as a thank you for their participation in the trial as 24 month parent completed outcome measures are requested.

We will seek parental consent to send parents additional neurodevelopmental measures during early childhood, as part of a separately funded study; we will submit an ethics amendment to provide details about this stage at a later date.

We will also seek parental consent to access the following routinely collected secondary care data at age 7 and 11 years: NHS data including hospital admissions, critical care and outpatient visits, developmental progress and diagnoses; Department for Education's National Pupil Database on school attainment tests and SEN at what is now known as Key Stages 1 and 2 (currently at ages 7 and 11 respectively, or at the corresponding ages if these change over the intervening period). We will apply for separate funding to investigate the long-term clinical, developmental and educational outcomes of nutritional supplementation.

8.3. Recruitment

Infants will be recruited from UK NHS tertiary neonatal units (NNUs). Information about the trial will be widely available using posters and banners throughout the NNUs, on information leaflets and information and videos on the study website. Eligible infants will be identified by the clinical care team and recruited by appropriately trained, delegated individuals.

8.3.1. Inter-hospital transfers

Participating neonatal units will be either:

1. A recruiting site where parents' consent is obtained and infants are recruited, randomised, and commence participation in the trial.

2. A continuing care site, which will continue to administer the supplement and collect trial data if a participating infant is transferred in from a recruiting site.

The responsibility for complete data collection and supporting families will lie with the recruiting site. Regulatory approvals will be in place to continue any trial related activities at continuing care sites.

Some infants may be transferred to continuing care sites, or discharged home (HIE stratum infants), before parents have had adequate time to consider the trial, or for consent to be obtained. These infants

should be identified by the recruiting site. In this event, the recruiting site will approach parents to provide trial information, address parental queries and complete the consent process remotely if parents wish to participate. This will be done by remote video or telephone discussion and consent either at the continuing care site, or at the family home on the days after discharge for HIE stratum infants (see section 8.5). This will be documented using the paper based Remote Consent Form.

For further details about commencing supplement at continuing care sites see section 9.1.3: Commencing Supplement.

8.4. Screening and eligibility assessment

Infants admitted to the NNU will be screened for eligibility by the clinical care team. Parents with legal responsibility will be approached to discuss the trial. Eligibility will be reconfirmed at the point of randomisation.

8.5. Informed consent

Parents with legal parental responsibility for infants identified as being potentially eligible will be approached to discuss the trial further and to request consent. Parents will be given the opportunity to consider the information, and to ask questions of the research team or other independent parties to decide whether they will participate in the trial. A trained and delegated individual must obtain appropriate informed consent from one parent with legal parental responsibility prior to any trial related procedures being undertaken. If the mother cannot be approached, maternal consent for the purposes of maternal data collection will be requested as soon as practically possible. Virtual or remote consent (via telephone or video call) will be accepted and will be documented on the paper based Remote Consent Form.

If consent is being taken in-person, the person with legal responsibility must sign and date the latest approved consent form and the delegated individual taking consent will sign and date the form. If the consent discussion takes place remotely, the person with legal responsibility will be provided with a patient information sheet either as a physical hard copy prior to the infant being discharged from the NNU, or as an electronic copy via an email or as a digital download. The Remote Consent Form will be used to record the consent process.

Regardless of the method of consent, a copy of the completed consent form will be given or emailed to the parent by the recruiting site, a copy will be stored in the site file, a copy will be stored in the infant's medical notes and a copy will be sent to the NPEU CTU.

8.6. Randomisation

Randomisation will occur as soon as possible after consent is obtained. For the preterm stratum this will be before the infant is discharged home from the NNU or continuing care unit. For the HIE stratum this will be until 40 weeks of gestation plus 28 days, and may occur pre or post discharge home.

Randomisation will use a 1:1 allocation ratio, with twins (or higher order multiple births) allocated to the same arm, to either:

(1) Active supplement: Micronutrient breast milk/formula milk/food supplement containing LCPUFAs, choline, UMP, and CMP.

or

(2) Matched placebo control supplement

Randomisation of infants will be managed via a secure web-based randomisation facility hosted by the National Perinatal Epidemiology Unit Clinical Trials Unit (University of Oxford) with telephone backup available at all times (365 days per year). Randomisation will be stratified according to the two strata: (1) Preterm infants born less than 28 weeks of gestation; and (2) Infants born at 35 weeks of gestation or more who receive therapeutic hypothermia for hypoxic ischaemic encephalopathy (irrespective of neuroimaging findings). The randomisation program will use a separate minimisation algorithm within each stratum to ensure balance between the intervention and control arms with respect to recruiting hospital and sex, and in addition for the preterm strata, gestational age at delivery (by week of gestation) and multiple births.

A Senior Trials Programmer at the NPEU CTU will write the web-based randomisation program and hold the treatment allocation codes. Pack numbers will be added by the Senior Trials Programmer, who will liaise directly with the packaging and distribution company. The Senior Trials Programmer and Trial Statisticians will monitor implementation of the randomisation procedure throughout the trial. Reports will be provided to the Data Monitoring Committee (DMC). An integrated web-based pack management system will track supplies of active supplement and placebo ensuring a balance of stock across sites and resupplies are according to the allocated arm.

8.7. Blinding and code-breaking

Families and clinical teams caring for the infant will be blinded to trial allocation. Centres will be supplied with sealed numbered packs containing active supplement or placebo supplement. Once consent and eligibility are established, infants will be allocated a pack containing the trial allocation generated by the randomisation process; the trial allocation itself will not be revealed. All investigators and CTU staff with the exception of the Senior Trials Programmer and Trial Statisticians will be blinded to trial allocation.

In the event of an emergency, unblinding can be performed by the clinician at the recruiting site by logging in to the randomisation website using a single-use access code provided in a sealed envelope. The reason for unblinding must be recorded in the randomisation database. Clinicians will be reminded to exercise discretion when the allocation has been unblinded.

Clinicians carrying out emergency unblinding must be satisfied that it is a genuine emergency and that knowledge of the treatment allocation (either active supplement or placebo) is needed to guide the appropriate clinical management of the infant. In most cases, appropriate clinical management will be possible without unblinding, by treating the infant as if they have received the active supplement.

Clinicians considering emergency unblinding are encouraged to discuss the need to do so with the PI or any clinician on the delegation log beforehand, if possible and safe to do so.

Where the infant has been transferred from the recruiting site for onward care, the treating health care professional should contact the PI or any clinician on the delegation log at the recruiting site to discuss unblinding.

As long-term neurodevelopmental follow-up of the cohort in future studies is planned, participants will not be unblinded at the end of the trial or until all future follow-up studies are completed. Thus, all other requests for unblinding must be made in writing to the NPEU CTU, who will consider the request in discussion with the Chief Investigator or delegate.

Participants will be made aware of the unblinding process/criteria in the Parent Information Sheet prior to consent being obtained.

8.8. Study data collection

Data for the trial include:

1) Parent completed measures:

At randomisation:

The mother (or other person with parental responsibility) will be asked to complete a baseline questionnaire seeking demographic information and a health related quality of life questionnaire (the EuroQol EQ-5D-5L).

Following discharge home:

The mother (or person with parental responsibility) will be asked to complete questionnaires to assess method of supplement delivery (including breast milk or infant formula feeding), supplement tolerability, any community health and social care contacts, any costs incurred by families, parental time away from work and informal care provided by friends or family. The mother will also be asked to complete the EuroQol EQ-5D-5L questionnaire. These questionnaires will be completed at regular intervals as listed in section 6, and alongside the neurodevelopmental outcome questionnaire measures at 24 months post EDD.

Respondents will be given the option of receiving and completing all questionnaires in paper copy by post, or electronically. All data will be entered on to the OpenClinica database on FREEPOST return or uploaded electronically depending on method of completion.

2) Routinely collected clinical data:

a. Until discharge home from the Neonatal Unit:

Clinical data relating to birth and NNU admission/stay will be collected from hospital records and the BadgerNet or equivalent electronic data collection systems, from trial entry to hospital discharge home.

All data will be entered on trial specific paper or electronic CRFs. The outcome CRF will be completed at the time of discharge from the hospital. If the infant is transferred to another hospital, a discharge CRF must be completed at the time of discharge from the recruiting site, and at the point of discharge from the unit the infant is transferred to. The recruiting site will be responsible for data collection.

b. Post-discharge home (24 months post EDD):

Clinical data will be collected from hospital records. All data will be entered on trial specific paper or electronic CRFs.

Parental consent will be obtained at trial entry requesting permission to follow up infants in the future using routine national databases.

8.9. Withdrawal of participants

Parents will have the right to withdraw their infant from the trial at any time. Withdrawal from the trial will not affect their infant's ongoing clinical care. They may withdraw consent for any aspect of the study and/or data collection. Data collected up to the point of withdrawal will be used in the trial.

Parents who wish to discontinue trial supplementation will be asked if they are still happy to complete data collection and give permission for the trial team to complete data collection using medical records. In addition, the treating clinician may discontinue the trial supplement at any time if they consider it to be in the best interests of the infant's health and wellbeing. The reason for discontinuation will be recorded on an eCRF, if a reason is given.

If there is a permanent or temporary discontinuation or interruption of supplementation by parent or clinician this does not constitute a withdrawal.

Withdrawals and deaths within 28 days of commencing the supplement will be replaced through additional trial recruitment; withdrawn infants or infants who have died will be included in the Intention to Treat analysis.

8.10. Definition of end of trial

The end of the trial will be defined as the date when the trial database is locked. An end of trial declaration will be made to the approving REC.

9. TRIAL INTERVENTIONS

This trial is classified as A Clinical Trial of a non-IMP. The active supplement is not classifiable as an investigational medicinal product therefore clinical trials authorisation from the MHRA is not required.

The active and placebo supplements have been developed, quality control checked and provided by Nutricia, a company that makes foods for medical nutrition. Nutricia is the only supplier of this particular supplement. Nutricia were not involved in the design of the study, nor will they be involved in the

collection or analysis of trial data. Depending on the findings of the trial, organisations such as the National Institute of Health and Care Research can decide if it should be offered through the NHS.

9.1. Intervention description

The intervention is a novel micronutrient breast milk/formula milk/food active supplement. The active supplement consists of a specific nutrient blend containing long-chain polyunsaturated fatty acids (LCPUFAs), choline, uridine-5'-Monophosphate (UMP), and cytidine-5'-monophosphate (CMP). The placebo supplement contains fractions of the active components in the investigational product and no UMP and CMP. The placebo product contains higher levels of lactose. The active and the placebo products are isocaloric, and have similar levels of fat and comparable energy content.

Powder supplement will be added daily to usual milk feed (breast or formula) on the neonatal unit after infants have reached full milk feeds (120–150ml/kg/day). A matched placebo supplement will be an identically packaged and delivered powder supplement indistinguishable from the active supplement. For HIE stratum babies, -in the event an eligible infant is discharged home without joining the trial, and/or starting supplementation, consent, training to give supplement, and commencement of supplement can be undertaken at home up to 28 days post discharge. The infant will be randomised in accordance with section 8.6. Supplementation will be continued on discharge until 12 months post EDD and can be added to weaning foods. Currently there are no specific nutritional recommendations made for newborn infants with brain injury.

Nutricia Research, the Netherlands designed, produced and supplied the supplements for the original Dolphin Trials [3,5]. Subsequent market research with Dolphin Trials' parent participants and product development work refined the supplement products and improved the overall product experience and acceptability, as confirmed during product testing with Dolphin Trials' parent participants.

The long-chain polyunsaturated fatty acids in the active supplement are from a fish source. The supplements contain small amounts of cow's milk protein. The supplements do not contain pork. They are not certified kosher and halal compliant.

To prepare the supplement in a clean and correct way the factory will clean the production line after each production. They will test the quality and safety of the supplements, (including microbiological safety testing). The supplements will be produced by the factory in 13g sachets. The sachets will be boxed in the factory. When the supplements are produced, tested and boxed they will be sent to an external warehouse where the boxes containing the supplements will be labelled for the study purposes. Each box will have a unique identifier code supplied by the NPEU CTU. Nutricia will store the boxed sachets and transport them to the UK. Boxes of supplement sachets will be stored in the UK and delivered to recruiting sites and to the participants' homes by a distribution company subcontracted by Newcastle upon Tyne Hospitals NHS Foundation Trust. Nutricia will have no access to child, parent or professional identifiable information (see Section 13, Data Management). Their branding will not be on the sachets or trial materials.

9.1.1. Blinding of supplement

The placebo supplement and the active treatment will be packaged in either a white or a foil sachet. The colour of the sachet bears no correlation as to whether it is the placebo supplement or the active treatment, and the content will be indistinguishable. See section 8.7 Blinding and code-breaking for further details.

9.1.2. Administration of supplement

The supplement will be provided in labelled sachets. Each box of supplement will contain a 1g scoop, with which to measure out supplement from the sachet. The measured supplement dose will either be dissolved into the infants' milk feed, or dissolved in a small volume of infant milk and given ahead of a feed. The amount of supplement will be 1g/kg i.e. 1 scoop per whole kilogram child weight i.e. an infant weighing 3.0 –3.9kg will receive 3 scoops daily. Infants weighing less than 1kg will receive a proportionate amount of supplement based on pre-defined weight bands i.e. an infant who weighs 0.5-0.74kg will receive 0.5g supplement; infants weighing 0.75-0.99kg will receive 0.75g of supplement. To make up 0.5g of supplement, NNU staff will follow guidance for making up 1g supplement (in a minimum of 3ml milk) then discard 50% of the total volume of milk mixed with supplement. To make up 0.75g of supplement, NNU staff will follow guidance for making up 1g supplement (in a minimum of 3ml milk) then discard 25% of the total volume of milk mixed with supplement.

Each 1g of supplement must be given with a total milk volume of at least 15ml of milk to ensure appropriate osmolality. For breastfed babies, 1g supplement can be mixed with a minimum volume of 3ml of milk and given before a feed, as long as the total feed volume is at least 15ml for each 1g of supplement. Infants who weigh less than 1kg will require a proportionate total feed volume i.e. infants receiving 0.5g of supplement will have a minimum total feed volume of 7.5ml, and infants receiving 0.75g of supplement will have a minimum feed volume of 11ml.

Infants receiving supplement dissolved in their usual milk feed will be given this via their normal feeding route e.g. oral, nasogastric tube, gastrostomy tube. Mothers of infants who are fed via nasogastric or gastrostomy tube will be supported with supplement delivery by a funded NHS clinical team at sites and via specifically developed trial materials.

Breastfeeding mothers will be provided with a range of options for delivering the supplement before a breast feed, including for example, use of a supplemental feeding system, syringe, teat, finger-feeder, or a cup. Depending upon the supplement delivery method chosen, breastfeeding mothers who choose to express the required volume of milk with which to mix the supplement, will be supported to do this through funded NHS clinical team at sites and specifically developed trial materials.

9.1.3. Commencing supplement

Infants must be on full milk feeds before commencing on either the active or the placebo supplement. The definition of 'full milk feeds' will vary slightly between NNUs, but in term infants these are typically around 120ml/kg/day whilst in preterm infants they are around 150ml/kg/day, or when parenteral nutrition is no longer considered necessary (exact timing at the discretion of the clinical consultant

managing their care), unless there is clinical indication not to do so. Infants recruited post-discharge up to 40 weeks plus 28 days will commence supplementation at home as soon as possible after randomisation.

The supplement can be given with one milk feed per day, using the infant's usual milk feed and according to maternal choice (breast milk (BM), donor breast milk (DBM) or formula milk). Parents who wish/need to provide the daily dose across more than one feed can do so. Whilst on the NNU, the supplement will be added to milk by milk-kitchen or nursing staff, or parents according to each NNUs standard approach. The supplement will be continued at home by parents post-discharge and continued to 12 months post EDD. This date will be provided to parents in the discharge information pack, and to local teams on infant trial entry.

In the event of a hospital transfer, supplementation will only continue where there are regulatory permissions in place at the continuing care site AND when supplementation has already commenced at the recruiting site. If a recruiting site completes the consent and randomisation process remotely, the supplementation will only be started as soon as possible on discharge home. When supplementation is already established at the recruiting site (and regulatory permissions are in place at the continuing care site), the infant will be transferred with sufficient supply of supplement for use at the continuing care site.

Further supplement will be delivered to the family home on final discharge using the distribution service.

9.1.4. Development of food intolerance during supplementation

The following allergens (according to directive 2003/89/EC) may be present in the product:

- Eggs and products thereof
- Fish and products thereof
- Milk and products thereof (including lactose)

If any of the following food intolerances/conditions are suspected and an exclusion diet trialled in an attempt to reach a conclusion, then supplementation will be suspended for the duration of the exclusion trial then re-started once an intolerance has been excluded:

- Established or expected cow's milk protein allergy
- Lactose intolerance
- Intolerance of eggs and products thereof
- Galactosaemia
- Fish protein allergy

This information is provided to parents in the discharge pack. The infant should continue with the trial procedures as documented in this protocol despite stopping supplementation.

9.2. Parent support and training to give supplement

The supplement can be given to infants who are breastfeeding, bottle feeding (either maternal breastmilk or DBM or formula milk), or nasogastric/gastrostomy tube (NGT/GT) feeding. Breastfeeding mothers will be provided with a range of options for delivering the supplement, including, for example, use of a supplemental feeding system, syringe, teat, finger-feeder or cup, or another system if that is preferred and used by local sites. In the days or weeks prior to hospital discharge, parents will be taught to mix and give the supplement to their infant by NNU staff. At discharge each family will be provided with aparent discharge pack, which will contain an initial supply of supplement, written support materials and access to online information and videos specific to each feeding method detailing: how to mix and give the supplement, dosing schedules, a personalised study timeline (with the infant's supplement end date and outcome measurement dates), and contact information for the infant's local NHS professionals and the research team. Generic versions of the materials will also be available via the trial website (https://www.npeu.ox.ac.uk/dolfin), which will include: videos on how to mix the supplement, breastfeeding support materials, nasogastric and gastrostomy tube feeding support materials. There will also be a frequently asked questions page, which will be regularly updated. Parents will also be signposted to the trial website via the app (or text) during app (or text) contacts.

9.3. Promotion, protection and maintenance of breastfeeding

The DOLFIN trial will utilise existing appropriate materials that are available widely or locally to support breastfeeding mothers. Prior to the trial commencing, focus groups with breastfeeding mothers of preterm and term infants will facilitate co-design of breastfeeding support materials for use during the trial. This will include written and video materials providing population specific breastfeeding advice, and demonstration of available methods for giving EBM mixed with supplement. Informed by this PPI work, methods to promote, protect and maintain breastfeeding will be employed as follows:

1. Recruiting NNUs will receive multi-use breast pumps for use by trial mothers when their infants are on the NNU.

2. Breastfeeding mothers will have a choice of delivery methods for giving the supplement. These include: use of a supplemental feeding system (SFS) known to be effective and acceptable to mothers (a thin flexible tube is taped to the nipple, the other end is placed in a plastic bottle containing supplement and breast milk; sucking facilitates simultaneous draw from the breast and from the bottle, the infant controls the flow rate), mixing the supplement with maternal choice of milk and giving via a syringe, teat, finger-feeder, or cup, or another safe system if that is preferred and used by local sites.

3. Signposting to local and national breastfeeding support.

4. Breastfeeding mothers will also be supported by local lactation consultants whose role will be supported by trial funding to sites.

9.4. Support for parents post discharge

Parents will be supported throughout the trial by their local neonatal and local post discharge clinical teams including paediatricians, dietitians, lactation consultants, as per usual care. This activity is supported through trial funded time for clinical staff at participating sites. Parents will be provided with information on who to contact with trial related queries (local research nurses or local post discharge clinical team, depending on local set-up). Members of the Project Management Group will respond to queries from local neonatal and local post discharge clinical teams as needed. The PMG may respond to direct queries from parents relating to trial processes, data collection or resupply of supplement; they will not become involved with queries relating to the clinical care of their infant. Queries relating to the clinical care of infants will be directed to the local neonatal and local post discharge clinical teams. If needed, the PMG will liaise with parents and with the local post discharge clinical team at sites as required to best support participating families.

9.5. Trial communication and adherence app

During the trial, parents will be invited to download a bespoke trial app, created in partnership with NuTH, and produced by Newcastle University, to facilitate communication with the research team and collection of adherence data (this will be GDPR compliant, and Sponsor approved). In the first stages of the trial, prior to the app being available, parents will also be able to contact the research team directly via individual WhatsApp accounts (text messages will be used for parents unwilling/unable to use the app or WhatsApp). WhatsApp, text message or email will only be used as a communication tool and will not be used to collect trial data. Any queries regarding clinical care will be directed to the local neonatal or local post discharge clinical team as appropriate, with whom the research team will liaise as required (see section 9.4 Support for parents post discharge and 9.6 – Support to local clinical teams).

9.6. Support to local clinical teams

Local neonatal and post discharge clinical teams will be supported by the clinical trial research team comprising paediatricians, dietitians, a research nurse and a lactation consultant. The research team nurse and co-investigator team will provide comprehensive training to local neonatal and post discharge nurses, lactation consultants, dieticians, and medical staff at site set-up. This will include face-to-face (remote or in person) training on the study and provision of comprehensive written trial reference materials within the site trial pack. The professionals' page hosted on the NPEU website will contain comprehensive materials and a frequently asked questions document. The research team will be in regular contact with local clinical teams, during the set up and recruitment and supplementation phases, to allow early identification and resolution of any challenges.

9.7. Supplement storage and supply

Nutricia will transport the supplement through the intervention phase to the UK storage facility. The supplement will be distributed to participating NNUs and direct to family homes via the distributor. Participants will be discharged with an initial supply of supplement, then receive further deliveries of

supplement through the supplementation stage. The number of deliveries will be determined by final product shelf-life, anticipated to be 9 months by trial commencement, or longer if Nutricia testing shows this is appropriate. The resupply of supplement across all sites will be closely monitored using an online pack management system that will track stock levels (including expiry dates) across sites and families. This will ensure full accountability of packs and resupply to families is in line with protocol requirements. The supplement has been tested and found to be stable to 30 degrees Celsius; NNUs and parents will store the supplement at ambient room temperature in a naturally cool area.

9.8. Post discharge supplementation period

9.8.1. Altering the amount of supplement received

During supplementation, parents will receive monthly requests for information about their infant's weight (regularly measured as standard care for this population; parents will be requested to weigh their infant monthly at a health clinic and enter the weight in a banding - for example 3-4 kg, 6-7kg). Parents will be sent (using text or email) a link to an OpenClinica Participate form into which they will enter their infant's current weight. They will then be sent a link to the trial website where the dosing schedule for each weight band can be viewed. This process will be replicated for parents using the app when it is available. Parents will also have a paper version of the dosing schedule in their discharge pack. Supplement dose will be equivalent to 1 scoop per whole kg child body weight (each scoop 1g), up to a maximum daily dose of 12g (for example a 3.6kg infant in the 3-4kg weight band receives 3 scoops). For the first 6 months, the local research nurse will telephone parents monthly to confirm the current correct dose on receipt of weight information, supported by the trial dietitians. If parents are confident of the dosing method, dose confirmation calls will cease thereafter. The app is not considered a medical device.

9.8.2. Adherence to trial supplement prior to discharge

Prior to hospital discharge, adherence will be recorded on eCRFs completed by the local research team to document whether the supplement has been given according to the protocol.

9.8.3. Adherence monitoring following discharge

For the first three months of supplementation post discharge, parents will be asked to confirm that they have given the supplement by responding to a daily email, text or app prompt. In response to PPI input, the frequency of reminders will then reduce to prevent contact fatigue; parents will be able to request to continue/discontinue daily reminders if they wish. This will allow the research team to identify parents who may need additional support to give the supplement. After the first three months post discharge, parents will also receive a weekly email, text or app prompt asking them to report the proportion of supplement they have managed to deliver over the previous week from a drop down menu. In cases of non-adherence, the research team will liaise with the post discharge clinical team to identify barriers to supplementation and offer appropriate support to improve subsequent adherence.

9.8.4. Accountability of the trial supplement

Families will be advised to dispose of unused or expired supplement by placing it in a domestic bin. There will be no product reconciliation. Adherence monitoring will be parent reported via the reporting mechanisms described in section 9.8.3.

9.8.5. Concomitant medications and dietary supplementation

There are no contraindicated medications or dietary supplements, and infants will be able to have all medicines and supplements normally prescribed for this population during the course of the trial. If parents choose to give additional dietary LCPUFA to their infant, this is not a concern as commercially available LCPUFA supplements are low and will not significantly alter the overall LCPUFA intake of participating infants.

9.8.6. Recruitment to other trials

Co-recruitment to other trials is permitted, except for intervention trials which have a neurodevelopmental primary outcome. Co-recruitment to another trial with a neurodevelopmental primary outcome may be possible following discussion and agreement between trial Chief Investigators.

Co-recruitment to the EDEN (Erythropoietin and Darbepoetin in Neonatal Encephalopathy) study is permitted for infants in the HIE stratum. Consent will be sought from parents with infants participating in both studies to enable the sharing of personal identifying and health outcome information collected in the DOLFIN study to be shared with the EDEN trial team, and be used for the purposes of that study. Subject to the appropriate regulatory approvals, parents participating in both DOLFIN and EDEN may also be asked for consent for the sharing of personal identifying and health outcome information collected in the EDEN study to be shared with the DOLFIN trial team, and be used for the purposes of that study. Examples of data which would be shared between studies includes, but is not limited to, neurodevelopmental outcome data and neuroimaging data. The shared information will be treated confidentially, in compliance with any applicable Data Sharing Agreement and will only be shared if informed consent is obtained.

9.8.7. Post-trial supplementation

There will not be the provision of the supplement beyond the trial period.

10. SAFETY REPORTING

10.1. Adverse Event Definitions

Adverse Event (AE)	Any untoward medical occurrence in a participant to whom a trial supplement has been administered, including occurrences which are not necessarily caused by or related to that product.
Adverse Reaction (AR)	Any untoward and unintended response in a participant which is

	related to the trial supplement.
Serious Adverse Event (SAE)	A serious adverse event is any untoward medical occurrence that: 1. results in death 2. is life-threatening 3. requires inpatient hospitalisation or prolongation of existing hospitalisation 4. results in persistent or significant disability/incapacity 5. consists of a congenital anomaly or birth defect Other 'important medical events' may also be considered a serious adverse event when, based upon appropriate medical judgement, the event may jeopardise the participant and may require medical or surgical intervention to prevent one of the outcomes listed above. NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.
Serious Adverse Reaction (SAR)	An adverse event that is both serious and, in the opinion of the reporting Investigator, believed with reasonable probability to be due to the trial supplement, based on the information provided.
Unexpected Serious Adverse Reaction	An SAE that, in the opinion of the CI (or safety delegate), is a result of the trial supplement and is not listed as an expected occurrence in the protocol.

NB: to avoid confusion or misunderstanding of the difference between the terms "serious" and "severe", the following note of clarification is provided: "Severe" is often used to describe intensity of a specific event, which may be of relatively minor medical significance. "Seriousness" is the regulatory definition supplied above.

10.2. Procedures for reporting Adverse Events

The safety reporting window for this trial will be from starting the supplement up to two weeks after completing the trial supplement period (12 months post EDD) for each participant. All trials run by the NPEU Clinical Trials Unit (NPEU CTU) follow the unit's safety reporting Standard Operating Procedure (Safety Reporting in Trials not using IMPs).

In this population we anticipate day-to-day fluctuations of pre-existing conditions, new conditions, and we anticipate a small number of deaths. As a result, many adverse events are foreseeable due to the nature of the participant population and their routine care/ treatment. Consequently, only those adverse events identified as serious will be reported for the trial.

10.2.1. Foreseeable SAEs which do not require expedited reporting via a SAE form

The following foreseeable SAEs are pre-defined trial outcomes or are events that could be reasonably expected to occur in this population. They do not require reporting by trial centres as SAEs unless considered that they may be causally related to the trial supplement, in which case they should be reported as detailed in Section 10.3:

Foreseeable serious adverse events:

1. Abnormalities of tone, posture and/or movement
2. Accidental injury
3. Anaemia
4. Clinically significant intracranial abnormality on cranial ultrasound scan – intracranial haemorrhage or white matter injury
5. Chronic lung disease / Broncho pulmonary dysplasia
6. Coagulopathy requiring treatment
7. Congenital anomalies
8. Death (unless unforeseen in this population)
9. Difficulty establishing enteral feeding
10. Dysphagia/neurological feeding and drinking difficulties
11. Epilepsy
12. Food intolerances leading to exclusion diet (cow's milk, lactose, eggs, fish)
13. Fluid retention
14. Fine motor impairment
15. Gastrointestinal bleeding
16. Global developmental impairment
17. Gross motor impairment
18. Haematuria
19. Haemothorax
20. Hearing impairment
21. High blood creatinine level (defined as >100 µmol/L)
22. Hyperbilirubinemia (jaundice)
23. Hyperglycaemia
24. Hypoglycaemia
25. Hypotension
26. Hypoxic ischaemic encephalopathy
27. Hydrocephalus
28. Impaired renal function (urine output <0.5 ml/kg/hour, and or serum creatinine > 100 µmol/L)
29. Low sodium level/hyponatremia
30. Liver dysfunction
31. Non-iatrogenic meningitis
32. Necrotising enterocolitis
33. Neutropenia (defined as <1.0 mmol/L)
34. Metabolic bone disease

35. Metabolic disturbance of electrolytes or minerals
36. Patent ductus arteriosus
37. Pneumothorax or air leaks
38. Pneumonia (including aspiration pneumonia)
39. Pulmonary haemorrhage
40. Pulmonary hypertension requiring treatment
41. Respiratory failure
42. Retinopathy of prematurity
43. Seizures
44. Sepsis / infection
45. Sleep disordered breathing
46. Spontaneous intestinal perforation
47. Speech and language impairment
48. Thrombocytopenia
49. Tracheostomy placement
50. Upper airway obstruction
51. Visual impairment

10.2.2. SAEs which require expedited reporting via SAE reporting form:

All SAEs other than those listed as foreseeable (section 10.2.1), and not deemed causally related, will be reported. Reporting procedures will be followed as per section 10.3. In particular, the following events will need to be reported:

- Serious prolonged gastrointestinal disturbance (except from necrotising enterocolitis)
- Serious prolonged gastrointestinal disturbance associated with culture/growth of an unusual organism
- Sepsis associated with culture/growth of an unusual organism

All SAEs deemed causally related to the trial supplement must also be reported as per section 10.3, irrespective if they feature in the list under 10.2.1.

10.3. Reporting procedures for Serious Adverse Events

During NNU admission, all unforeseeable SAEs, and foreseeable SAEs deemed causally related to the trial supplement (as defined in section 10.2.2) must be reported on the SAE Reporting Form to the NPEU CTU trial team as soon as possible after the site becomes aware of the event being defined as serious.

Following discharge from the NNU, parents will be asked to report SAEs to their local research nurse or post discharge clinical team using contact details provided in discharge trial packs. Parents will also be asked about the occurrence of SAEs at the time of parent reported outcome measure completion at 3, 6 and 12 months post EDD. SAEs reported to the local research nurse or post discharge clinical team (which meet the reporting criteria listed above), must be reported to the NPEU CTU trial team via the

SAE Reporting Form as soon as possible after the individual being made aware of the event being defined as serious.

SAE information will also be obtained via a CRF completed by the local research nurse or local clinical team at 12 months by accessing routinely collected NHS health data.

Sites may use one of the following SAE reporting methods:

1. Paper forms, with instructions, will be provided with the trial documentation to enable anyone to report an SAE. The completed SAE form must be emailed to NPEU CTU.
2. Staff with access to the trial electronic database should complete the SAE form online. An automatic email notification to the NPEU CTU staff will be triggered for SAEs reported electronically.
3. Where the above routes are not possible, then the SAE may be reported to NPEU CTU by telephone and the SAE form will be completed by NPEU CTU staff in compliance with internal NPEU CTU safety reporting Standard Operating Procedures (SOPs).

Follow-up SAE information should be reported as necessary by the site staff and sent back to the NPEU CTU electronically or by email.

All reportable SAEs as defined in this protocol will be forwarded to Nutricia as set out in the Product Supply Agreement.

10.4. Assessment of causality

The relationship of each adverse event to the trial supplement must be determined by a medically qualified individual according to the following definitions:

- **Unrelated** – where an event is not considered to be related to the trial supplement.
- **Possibly** – although a relationship to the trial supplement cannot be completely ruled out, the nature of the event, the underlying disease, concomitant medication or temporal relationship make other explanations possible.
- **Probably** – the temporal relationship and absence of a more likely explanation suggest the event could be related to the trial supplement.
- **Definitely** – the trial supplement is the most likely cause.

All SAEs labelled possibly, probably or definitely will be considered as related to the trial supplement.

10.5. Review of SAEs

The NPEU CTU will forward a copy of the SAE form to the CI / safety delegate as soon as possible on receipt. The CI /safety delegate will also (as well as the site PI) assess whether the SAE was related to the trial supplement (i.e. is it an SAE or a SAR). If assessed to be related, the CI / safety delegate (Jeremy Parr, Morag Andrew, Nicholas Embleton, or Charles Roehr) will proceed to assess expectedness (see Section 10.5.1).

10.5.1. Assessment of expectedness

Assessment of whether a serious adverse reaction is expected will be made according to the list below. Expected events are:

- Serious prolonged gastrointestinal disturbance (except from necrotising enterocolitis)
- Serious prolonged gastrointestinal disturbance associated with an unusual organism
- Sepsis associated with an unusual organism

All other related SAEs will be considered unexpected and reported as described in section10.6.

10.6. Reporting Unexpected Serious Adverse Reactions

All unexpected SARs will be submitted to the REC that gave a favourable opinion of the study within 15 days of the CI becoming aware of the event, using the HRA report of serious adverse event form (see HRA website). As the study is blinded, the blind will be broken for the participant concerned by the Senior Trials Programmer or delegate, who will then carry out the required reporting. These unexpected SARs will also be reported to the DMC in an unblinded format. The Sponsor, Site PIs and relevant R&D offices will receive a summary of the USAR in a blinded format to prevent unnecessary unblinding. The NPEU CTU will forward all related unexpected SARs to Nutricia within 72 hours after NPEU CTU receives an SAE Reporting Form from the trial site investigator.

11. STATISTICS

11.1. Sample size determination

To detect a 6 point difference between two trial arms on the PARCA-R non-verbal cognitive scale standardised score (for both strata), with 90% power and a 2-sided 5% significance, assuming a population mean score of 88 and standard deviation of 19, 212 infants per arm are required for each stratum (424 in the preterm stratum and 424 in the HIE stratum). The estimated mean and standard deviation are from infants born less than 28 weeks of gestation in the PANDA study (used as validation sample for PARCA-R standardisation)(6); we assume similarly for infants of ≥ 35 weeks gestation with HIE.

An inflation factor of 14% applied to the preterm stratum allows for clustering due to infants from multiple births being randomised to the same allocation and gives a total of 484 infants (assuming prevalence of multiples of 30% and intra-cluster correlation coefficient of 0.77, data from SIFT trial)(15). Prevalence of multiples in the HIE stratum is expected to be negligible. Allowing for 10% loss to follow-up at 2 years of age gives an overall sample size of 538 (269 per arm) in the preterm stratum and 472 (236 per arm) in the HIE stratum. The total target sample size is 1,010 infants.

Thirty tertiary NNUs who confirmed ability to recruit to the trial during the NNU survey, and who have recruited well to previous NPEU trials will be approached as sites. Assuming a conservative parental uptake rate of 50%, we estimate recruitment will be 1–2 infants per NNU per month for both strata combined.

11.2. Statistical analysis plan (SAP)

The statistical aspects of the study are summarised here with details fully described in a statistical analysis plan that will be available prior to the first DMC review of interim data. The SAP will be finalised before final data lock takes place.

11.3. Description of statistical methods

The trial is powered to detect differences in the two trial strata (preterm and HIE) separately, and data will be analysed and presented separately for each stratum. Overall results by allocation for the two strata combined will not be presented. The primary inference will be based on a modified intention to treat (ITT) analysis, i.e. infants with outcome data will be analysed in the groups into which they were randomly allocated, regardless of allocation received.

The flow of participants through each stage of the trial will be summarised by randomised group using a CONSORT diagram, separately for the preterm and HIE strata. The number and percentage of infants lost to follow-up will be reported with the reasons recorded. Socio-demographic characteristics of the mothers, and clinical characteristics of the infants at baseline will be reported by trial allocation. For binary and categorical variables, the number and percentage in each category will be presented. For continuous variables, the mean and standard deviation or the median and the interquartile range will be presented. There will be no planned tests of statistical significance performed for differences between randomised groups on any baseline variable.

The mean and standard deviation will be presented for the standardised PARCA-R non-verbal cognitive scale score at 24 months post EDD by randomised group. A mixed-effects linear regression model will be fitted, adjusting for minimisation factors and the correlation between infants from multiple births. Collaborating hospital will be treated as a random effect in the model, with mother's identification nested within site and all other minimisation factors fitted as fixed effects. The adjusted mean standardised scores will be reported by randomised group, along with the adjusted mean difference and 95% confidence interval. A similar analysis approach will be adopted for other continuous outcomes, unless they are highly skewed, in which case quantile regression methods will be used and median differences with 95% confidence intervals will be presented.

Standardised PARCA-R scores cannot be calculated for infants if questionnaires are completed outside of 23.5 to 27.5 months post EDD, although their raw scores may be available. A multiple imputation analysis will be performed, imputing standardised scores for such infants. Estimates from the multiple imputation analysis will be presented as the primary inference and further sensitivity analyses will be documented in the SAP.

For dichotomous outcomes, risk ratios and 95% confidence intervals will be estimated using a log-binomial regression model, or a Poisson regression model with robust variance estimator if the binomial model fails to converge. Growth measurements (height, weight and head circumference) will be converted to standard deviation scores and analyses will be adjusted for baseline growth scores. These models will also be adjusted for minimisation factors and the correlation between infants from multiple births.

The consistency of the effect of the active supplement on the primary outcome will be assessed across specific subgroups of infants using the statistical test of interaction. Effect estimates and 95% confidence intervals will be presented for each subgroup, plus the interaction p-value.

The subgroup categories are:

- Gestational age at birth by week of gestation for the preterm stratum
- Severity of Hypoxic Ischaemic Encephalopathy (normal/mild, moderate, severe) according to neurological examination on days 1, 2 and 3 of therapeutic hypothermia for the HIE stratum.

A two-sided 5% level of significance will be used for all statistical tests, and 95% confidence intervals will be presented for all pre-specified outcome comparisons including subgroup analyses.

11.4. Health economics analysis

A cost-effectiveness analysis to determine whether the potential benefits of active supplement added to usual milk feed compared to usual milk without supplement represents value for money will be conducted separately for the preterm and HIE strata. A health economics analysis plan (HEAP) with extended details of the summarised costs-effectiveness methods presented in this proposal will be prepared in a separate document. The HEAP will be prepared and finalised before final data lock takes place.

We have designed a two-stage economic evaluation to assess: 1) whether the resources needed to deliver active supplement in practice are justified by the additional benefits achieved at 24 months; and 2) to estimate the cost-effectiveness of the intervention compared to the control group up to 18 years of age. In the first stage, we will conduct a within-trial cost-effectiveness analysis using the trial primary outcome as the health outcome measure for the economic evaluation, but the results of the study will also be presented as a cost-consequence evaluation in a secondary analysis. In the second stage, we will estimate a cost-utility analysis using a decision analytical model.

Stage 1: Within-trial cost-effectiveness analysis at 24 months corrected age

An NHS health care and societal perspective will be used in the within-trial cost-effectiveness analysis with categories of resource use relevant to each perspective captured. To minimise burden to families, we will extract secondary care data from hospital records at each site. We will circulate parents a questionnaire when infants are 6, 12, 18 and 24 months corrected age to collect health care utilisation details not available in hospital records (primary and community health and social care usage), any major specialist items purchased by families or home adaptations for the care of their infants; changes in parents' work pattern or time away from work, additional informal care/support required. We will conduct a micro-costing approach to determine the cost of delivering the intervention in practice to the NHS and families. Categories of resource use will be costed using national average unit costs from established sources including, for example, NHS Reference Costs and the Personal and Social Services Research Unit.

The main health outcome measure of the economic evaluation in this first stage will be defined as life years without moderate/severe neurodevelopmental impairment at 24 months corrected age. We will also collect maternal EuroQol EQ-5D-5L data to understand whether the intervention also affects mothers' health-related quality of life over the trial period.

Mean incremental analysis of costs and life-years without moderate/severe impairment between active and placebo supplements will be synthesised using the incremental cost-effectiveness ratio (ICER), which will be expressed as cost per life years without moderate/severe delays gained. Uncertainty around that estimate will be presented using parametric and non-parametric confidence intervals for the ICER (if appropriate) and cost-effectiveness acceptability curves (CEAC). Cost-effectiveness results will be presented separately for infants born <28 weeks gestation and those born at term who receive therapeutic cooling.

As a secondary analysis, we will also present the Stage 1 within-trial economic evaluation using a cost-consequence analysis. Costs will be presented alongside the key primary and secondary outcomes by treatment arm with associated uncertainty (for example PARCA-R, SDQ, parental acceptability, maternal health-related quality of life) an approach which will enable various stakeholders (for example parents, clinicians) to contemplate the impact of active supplement on the outcomes of most relevance to them.

Stage 2: Long-term cost-effectiveness analysis

If intervention with a nutrient enriched diet is shown to be cost-effective in Stage 1 for any of the infant population strata, we will develop a decision analytical model to estimate the cost-effectiveness of the intervention up to 18 years of age. This analysis will be conducted from a societal perspective and the main outcome measure in the economic evaluation will be child quality-adjusted life years (QALYs). A Markov model will be constructed representing the natural history of infants born <28 weeks gestation or born at term who receive therapeutic cooling to extrapolate the within-trial cost-effectiveness results using annual cycles. The structure of the model will be established and agreed within the research team. Observed outcomes and health care resource utilisation for randomised infants will be used to inform the characteristics of a hypothetical cohort entering the model. Transition probabilities indicating movement across health states during the first two years will be obtained from the trial, whereas transition probabilities after the second year will be informed through literature searches. Health care costs and health-related quality of life estimates incurred annually in each health state after the second year will be obtained from the literature. Data on informal care and impact on productivity of parents to inform cost parameters in the model will also be obtained from the literature.

Costs and QALYs will be combined and synthesised using the ICER and the net-benefit statistic. Uncertainty will be assessed using probabilistic sensitivity analysis and CEACs. These results will be presented from an NHS perspective and a societal perspective. One-way sensitivity analysis will be carried out to explore the impact of parameters not subject to probabilistic uncertainty (e.g. cost of active supplement to the NHS) on cost-effectiveness results.

11.5. Procedures for reporting any deviation(s) from the original statistical plan

Deviations from the Original Statistical Plan agreed by the co-investigators will be reported to the Trial Steering Committee, and the NIHR.

12. DATA MANAGEMENT

The data management aspects of the trial will be fully described in the Data Management Plan to ensure that high quality data are produced for statistical analysis.

12.1. Source data

Source documents are where data are first recorded, and from which infants' CRF data are obtained. CRF entries will be considered source data if the CRF is the site of the original recording (i.e. there is no other written or electronic record of data). Parent reported data (for example, adherence data collected via the app, Quality of life data and PARCA-R questionnaires) will be considered source data.

12.2. Access to data

Direct access will be granted to authorised representatives from the Sponsor, funder, research team, host institution (NHS trust) and the regulatory authorities to permit trial-related monitoring, audits and inspections.

Site staff will have authenticated and restricted access to the Clinical Database Management System (OpenClinica), ensuring they are only able to see data on participants recruited at their Trust. Access to the electronic data is strictly controlled using individual passwords for all staff accessing the electronic databases.

There will be no direct sharing of patient identifiable information or professionals' details with Nutricia. NuTH will share data with Nutricia as per the conditions stated in the Product Supply Agreement (which has been reviewed by the NIHR IP Team). Data will be shared with Nutricia in either a wholly anonymised format or pseudo-anonymised format, as per the terms of the Product Supply Agreement between Newcastle upon Tyne Hospitals NHS Foundation Trust and Nutricia.

12.3. Data recording and record keeping

All clinical data will be entered directly into the clinical database by the local NHS site staff. The clinical database will be validated and maintained in accordance with NPEU CTU Standard Operating Procedures (SOPs). Data will be entered and at the point of entry and will undergo a number of validation checks to verify the validity and completeness of the data captured. A separate administrative database application will be used to store the participants' names and any other identifiable details. Trial participants will be identified by a unique trial number, which is used to link the clinical and administrative database applications.

Regarding the DOLFIN parent app that will be created during the trial period, the digital app supplier will hold some personal details such as names, email address and contact details to facilitate usage of the

app but will not share this with other organisations. Consent forms containing the infant and parent's names will be sent securely electronically (using encryption) or in pre-addressed envelopes to the NPEU CTU. All data will be processed in line with the NPEU CTU Data Management SOPs. It is the responsibility of all parties involved (Sponsor, NPEU CTU, and the NHS organisations) to ensure confidentiality of participant information is maintained.

Electronic files, such as eCRFs and other electronic or scanned documents containing personal/sensitive information, will be stored on a restricted access (named individuals) server that can be accessed only by members of the NPEU CTU DOLFIN trial team with permissions to access data at specified levels, held in a secure location. The data are backed up daily. Authorised access to the NPEU CTU is via an electronic tag entry system and individual rooms are kept locked when unoccupied. Authorised staff will process data via a secure network, which requires individual login name and password (changed regularly). No data are stored on individual workstations.

Archiving will follow the completion of the trial and publication of results as detailed in NPEU SOPs and in line with NHS guidelines for a minimum of 25 years. At this point, the requirements to continue to archive these data will be reviewed in line with the applicable data protection guidelines.

All paper and electronic data will be stored securely in strict compliance with data protection regulations.

At the end of the trial, all participant clinical and parent-reported data (collected within OpenClinica) will be transferred to the research team at Newcastle University and NuTH. In addition, all participant names and NHS numbers, and parent names and contact details, will be transferred to the research team at Newcastle University and NUTH in order to allow Newcastle University and NuTH to contact parents if required at the end of the study or (for those who have consented) with regards to planned long-term follow-up, and in compliance with any applicable Data Sharing Agreement.

13. QUALITY ASSURANCE PROCEDURES

13.1. Risk assessment

The trial will be conducted in accordance with the current approved protocol, GCP, relevant regulations and SOPs. A risk assessment (RA) and monitoring plan (MP) will be prepared before the trial opens and will be reviewed as necessary over the course of the trial to reflect significant changes to the protocol or outcomes of monitoring activities.

13.2. Monitoring

The PI will be responsible for the running of the trial at their site. This will include ensuring successful recruitment, staff education and training, and trial data completeness and quality.

The NPEU CTU will develop an appropriate central monitoring plan for the trial, based on the RA. Recruitment patterns at sites and within the data will be monitored. Any unexpected patterns, issues, or outlier data will be investigated and may trigger 'for cause' site monitoring. No other routine monitoring or auditing will be conducted unless the central monitoring triggers cause to do so.

13.3. Trial committees

The trial will be run on a day-to-day basis by the Project Management Group (PMG), which reports to the Trial Steering Committee (TSC), which in turn is responsible to the NIHR HTA programme (as per the NIHR HTA contract). The PMG will consist of the Chief Investigator(s), CTU Director, Clinical CTU Director, Senior Trials Manager, the Trial Statistician, Sponsor and other project staff. The PMG will meet every month.

The Co-Investigator Group (CIG), an extended PMG, will comprise all members of the co-applicant group and the members of the PMG to review progress, troubleshoot and plan strategically.

The trial will be overseen by a TSC consisting of an independent chair and other members to include clinicians, statisticians and Patient and Public Involvement (PPI) representatives. Committee members will be deemed independent if they are not involved in trial recruitment. The chair and members of the TSC will be nominated as per the guidance outlined by the NIHR HTA for their approval. The TSC will aim to meet in person or virtually at least annually.

The TSC terms of reference are specified by the NIHR HTA. The TSC will monitor the progress of the trial and its conduct and advise on its scientific credibility. The TSC will consider and act, as appropriate, upon the recommendations of the DMC and ultimately carry the responsibility for deciding whether a trial needs to be stopped on grounds of safety or efficacy.

The Data Monitoring Committee (DMC) members will be independent of the trial team and the TSC, and will include a chair, clinician and statistician. During the recruitment phase, the committee will meet annually or more often as appropriate, review trial conduct, progress and accumulating data, and make recommendations to the TSC. Details about the roles, responsibilities and conduct of the committee will be set out in a DMC Charter, which will be agreed at the first meeting.

14. PROTOCOL DEVIATIONS

A trial related deviation is a departure from the ethically approved trial protocol or other trial document or process (e.g. consent process) or from GCP or any applicable regulatory requirements. Any deviations from the protocol will be documented in incident forms and, where applicable, the relevant corrective and preventative action completed. All incidents will be recorded in an Incident Log database.

15. SERIOUS BREACHES

A "serious breach" is a breach of the protocol or of the conditions or principles of Good Clinical Practice which is likely to affect to a significant degree –

(a) the safety or physical or mental integrity of the trial subjects; or

(b) the scientific value of the research.

In the event that a serious breach is suspected, the Sponsor must be contacted within 1 working day. In collaboration with the CI, the serious breach will be reviewed by the Sponsor and, if appropriate, the Sponsor will report it to the approving REC committee and the relevant NHS host organisation within seven calendar days.

16. ETHICAL AND REGULATORY CONSIDERATIONS

16.1. Declaration of Helsinki

The Investigator will ensure that this trial is conducted in accordance with the principles of the Declaration of Helsinki.

16.2. Guidelines for Good Clinical Practice

The Investigator will ensure that this trial is conducted in accordance with relevant regulations and with Good Clinical Practice.

16.3. Approvals

Following Sponsor approval, the protocol, informed consent form, participant information sheet and any proposed advertising material will be submitted to an appropriate Research Ethics Committee (REC), and HRA (where required) and host institutions for written approval.

The NPEU CTU will submit and, where necessary, obtain approval from the above parties for all substantial amendments to the original approved documents.

16.4. Other ethical considerations

There are no other ethical considerations associated with the trial.

16.5. Reporting

The CI shall submit once a year throughout the study, or on request, an annual progress report to the REC Committee, HRA (where required), host organisation, Sponsor and funder (where required). In addition, an end of study notification and final report will be submitted to the same parties.

16.6. Transparency in research

Prior to the recruitment of the first participant, the trial will have been registered on a publicly accessible database.

Where the trial has been registered on multiple public platforms, the trial information will be kept up to date during the trial, and the CI or their delegate will upload results to all those public registries within 12 months of the end of the trial declaration.

16.7. Participant confidentiality

The trial will comply with the GDPR and Data Protection Act 2018. All documents will be stored securely at the NPEU CTU and will only be accessible by trial staff and authorised personnel. The trial staff will safeguard the privacy of participants' personal data.

All personal identifiers details and trial data will be stored in a separate database also held at the NPEU CTU and at Newcastle University. These databases will only be linked by the infant's trial number. After the trial has been completed and the reports published, the data will be archived in a secure physical or electronic location with controlled access.

16.8. Expenses and benefits

Parents will receive a £25 thank you voucher for completion of the questionnaires; this will be sent as the 2 year parent completed outcome measure completion is requested.

16.9. Funding

This trial is funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) [NIHR130925]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Nutricia will fund active and placebo supplement production, supply and distribution to Trusts and homes. The Terms and Conditions of supply, including data sharing, are described in the Product Supply Agreement between Newcastle upon Tyne Hospitals NHS Foundation Trust and Nutricia.

16.10. Insurance

The Newcastle upon Tyne Hospitals NHS Foundation Trust is the sponsor for the trial. They have NHS indemnity in place which would operate in the event of any participant suffering harm as a result of their involvement in the research. NHS indemnity operates in respect of the clinical treatment which is provided. Newcastle University will indemnify the design of the trial.

16.11. Contractual arrangements

Appropriate contractual arrangements will be put in place with all third parties.

17. PUBLICATION POLICY

The success of the trial depends on a large number of neonatal nurses, neonatologists, and parents support of the trial. Credit for the trial findings will be given to all who have collaborated and

participated in the trial, including all local co-ordinators and collaborators, members of the trial committees, the DOLFIN Co-ordinating Centre and trial staff. Authorship at the head of the primary results paper will take the form "[name], [name] and [name] on behalf of the 'The DOLFIN Collaborative Group'". The drafting of the paper will be the responsibility of a writing committee. All contributors to the trial will be listed at the end of the main paper, with their contribution identified. It is the intention of the DOLFIN Collaborative Group to publish the protocol and peer-reviewed articles including the analysis of key outcomes. All published material will contain an acknowledgement of funding, as required by the NIHR HTA.

Parents will be emailed a copy of the trial results, and trial results will be disseminated through the trial website. A full dissemination plan will be developed by the PMG.

18. DEVELOPMENT OF A NEW PRODUCT/ PROCESS OR THE GENERATION OF INTELLECTUAL PROPERTY

Ownership of IP generated by employees rests with the employer.

Ownership of IP generated by employees of NuTH vests in NuTH. The protection and exploitation of any new IP will be managed by Newcastle University's IP team.

19. ARCHIVING

Archiving will follow the completion of the trial and publication of results as detailed in NPEU Standard Operating Procedures (SOPs) and in line with Sponsor's guidelines for a minimum of 25 years. At this point, the requirements to continue to archive these data will be reviewed in line with the applicable data protection guidelines.

20. ANTICIPATED TIMELINE



21. REFERENCES

1. Sakamoto T, Cansev M, Wurtman RJ. Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. 2007 11/28/2007; 1182:50-9.

2. Holguin S, Martinez J, Chow C, Wurtman R. Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J. 2008 11/2008;22(11):3938-46.

3. Andrew MJ, Parr JR, Montague-Johnson C, Laler K, Holmes J, Baker B, et al. Neurodevelopmental outcome of nutritional intervention in newborn infants at risk of neurodevelopmental impairment: the Dolphin neonatal double-blind randomized controlled trial. Developmental medicine and child neurology. 2018 Sep; 60(9):897-905. PubMed PMID: 29806081. Epub 2018/05/29.

4. Bayley N. The Bayley Scales of Infant and Toddler Development. III ed. San Antonio, TX: Pearson; 2006 2006.

5.Andrew MJ, Parr JR, Montague-Johnson C, Laler K, Qi C, Baker B, et al. Nutritional intervention and neurodevelopmental outcome in infants with suspected cerebral palsy: the Dolphin infant double-blind randomized controlled trial. Developmental medicine and child neurology. 2018 Sep; 60(9):906-13. PubMed PMID: 29023666. Epub 2017/10/13.

6. Kaufman AS KN. Kaufman assessment battery for children. Circle Pines: American Guidance Service; 1983.

7. Breckenridge K, Braddick O, Atkinson J. The organization of attention in typical development: a new preschool attention test battery. Br J Dev Psychol. 2013 Sep;31(Pt 3):271-88. PubMed PMID: 23901842. Epub 2013/08/02.

8. Atkinson J, 2021, Braddick O, Montague-Johnson C et al. Visual attention and dietary supplementation in children with perinatal brain injury. Dev Med Child Neurol. Epub 2021/08/27

9. Breeman LD, Jaekel J, Baumann N, Bartmann P, Wolke D. Preterm Cognitive Function Into Adulthood. Pediatrics. 2015 Sep;136(3):415-23. PubMed PMID: 26260714. Epub 2015/08/12.

10. Lin L, Amissah E, Gamble GD, Crowther CA, Harding JE. Impact of macronutrient supplements for children born preterm or small for gestational age on developmental and metabolic outcomes: A systematic review and meta-analysis. PLoS medicine. 2019 Oct;16(10):e1002952. PubMed PMID: 31665140. Pubmed Central PMCID: PMC6821063. Epub 2019/10/31.

11. Johnson S, Hennessy E, Smith R, Trikic R, Wolke D, Marlow N. Academic attainment and special educational needs in extremely preterm children at 11 years of age: the EPICure study. Archives of disease in childhood Fetal and neonatal edition. 2009 Jul;94(4):F283-9. PubMed PMID: 19282336. Epub 2009/03/14.

12. Basten M, Jaekel J, Johnson S, Gilmore C, Wolke D. Preterm Birth and Adult Wealth: Mathematics Skills Count. Psychological science. 2015 Oct;26(10):1608-19. PubMed PMID: 26324513. Epub 2015/09/02.

13. Lindstrom K, Lagerroos P, Gillberg C, Fernell E. Teenage outcome after being born at term with moderate neonatal encephalopathy. Pediatr Neurol. 2006 Oct;35(4):268-74. PubMed PMID: 16996401. Epub 2006/09/26.

14. Marlow N, Rose AS, Rands CE, Draper ES. Neuropsychological and educational problems at school age associated with neonatal encephalopathy. Archives of disease in childhood Fetal and neonatal edition. 2005 Sep;90(5):F380-7. PubMed PMID: 16113154. Pubmed Central PMCID: Pmc1721935. Epub 2005/08/23.

15. Perez A, Ritter S, Brotschi B, Werner H, Caflisch J, Martin E, et al. Long-term neurodevelopmental outcome with hypoxic-ischemic encephalopathy. The Journal of pediatrics. 2013 Aug;163(2):454-9. PubMed PMID: 23498155. Epub 2013/03/19.

16. Natarajan G, Pappas A, Shankaran S. Outcomes in childhood following therapeutic hypothermia for neonatal hypoxic-ischemic encephalopathy (HIE). Seminars in perinatology.

2016 Dec;40(8):549-55. PubMed PMID: 27863707. Pubmed Central PMCID: PMC5370563.

Epub 2016/11/20.

17. Samantha Johnson, Vasiliki Bountziouka, Peter Brocklehurst , Louise Linsell , Neil Marlow, Dieter Wolke, Bradley N, Manktelow. Standardisation of the Parent Report of Children's Abilities-Revised (PARCA-R): a norm-referenced assessment of cognitive and language development at age 2 years. Lancet Child Adolesc Health 2019 Oct;3(10):705-712. doi: 10.1016/S2352-4642(19)30189-0. Epub 2019 Aug 8

18. National Institute for Health and Care Excellence. Developmental follow-up of children and young people born preterm. NICE Guidance NG72; 2017.

19. International Consortium for Health Outcomes Measurement. Preterm and Hospitalized Newborn Health Standard Set; ICHOM, 2020

22. APPENDIX D: AMENDMENT HISTORY

Amendment No.	Protocol Version No.	Date issued	Author(s) of changes	Details of Changes made
1	3.0	09.06.2022	Sarah Turner	Minor wording amends including improvements in delivering the study supplement to a baby has been bench tested. The supplement can now be prepared with 3ml of milk for each 1g of supplement. Previously 15ml of milk was required for each 1g of supplement. With lower ml of milk required per 1g of supplement, a baby can now begin the supplement once they have reached full feeds, and no longer needs to wait until they have reached 1kg. Further information has been added to the protocol to inform participants about the supplement supplier (Nutricia's) involvement in the study. Explicit detail has be added to the protocol and supporting

				documentation regarding the supplement's suitability for participants on vegan, halal or kosher diets.